Envestnet Asset Management
CSTL icon

Envestnet Asset Management’s Castle Biosciences CSTL Stock Holding History

Envestnet Asset Management’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.32M Sell
55,157
-6,708
-11% -$149K ﹤0.01% 3449
2026
Q1 		$1.52M Sell
61,865
-101
-0.2% -$3.31K ﹤0.01% 3194
2025
Q4 		$2.41M Sell
61,966
-4,962
-7% -$160K ﹤0.01% 2690
2025
Q3 		$1.52M Sell
66,928
-3,550
-5% -$72.1K ﹤0.01% 3072
2025
Q2 		$1.44M Buy
70,478
+707
+1% +$13.1K ﹤0.01% 3040
2025
Q1 		$1.4M Sell
69,771
-3,573
-5% -$88.5K ﹤0.01% 2977
2024
Q4 		$1.95M Buy
73,344
+5,958
+9% +$181K ﹤0.01% 2695
2024
Q3 		$1.92M Buy
67,386
+20,289
+43% +$516K ﹤0.01% 2684
2024
Q2 		$1.03M Buy
47,097
+1,170
+3% +$26.1K ﹤0.01% 3030
2024
Q1 		$1.02M Sell
45,927
-4,100
-8% -$89.2K ﹤0.01% 3021
2023
Q4 		$1.08M Sell
50,027
-3,956
-7% -$69.6K ﹤0.01% 2889
2023
Q3 		$912K Buy
53,983
+18,469
+52% +$323K ﹤0.01% 2879
2023
Q2 		$487K Buy
35,514
+10,849
+44% +$220K ﹤0.01% 3224
2023
Q1 		$560K Buy
24,665
+2,273
+10% +$55.5K ﹤0.01% 3062
2022
Q4 		$527K Sell
22,392
-254
-1% -$5.89K ﹤0.01% 3073
2022
Q3 		$591K Buy
22,646
+48
+0.2% +$1.35K ﹤0.01% 2909
2022
Q2 		$496K Sell
22,598
-16,178
-42% -$376K ﹤0.01% 3053
2022
Q1 		$1.74M Buy
38,776
+5,337
+16% +$221K ﹤0.01% 2286
2021
Q4 		$1.43M Buy
33,439
+441
+1% +$23K ﹤0.01% 2379
2021
Q3 		$2.19M Buy
32,998
+2,576
+8% +$181K ﹤0.01% 2033
2021
Q2 		$2.23M Buy
30,422
+22,569
+287% +$1.49M ﹤0.01% 1981
2021
Q1 		$538K Buy
+7,853
New +$590K ﹤0.01% 2800

Other funds holding CSTL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Envestnet Asset Management's CSTL Position: Q2 2026 in Review

Envestnet Asset Management reduced its Castle Biosciences (CSTL) stake by 11% in Q2 2026, selling an estimated $149K and leaving 55,157 shares worth $1.32M. The position accounts for ﹤0.01% of the portfolio, ranked #3449.

Envestnet Asset Management first reported a position in CSTL in Q1 2021 and has held it in 22 quarters since. The position peaked at $2.41M in Q4 2025. 177 funds tracked by Wall St. Rank hold CSTL as of Q2 2026.

  • Envestnet Asset Management held 55,157 shares of Castle Biosciences worth $1.32M as of Q2 2026.
  • Envestnet Asset Management sold 6,708 Castle Biosciences shares in Q2 2026, an estimated $149K.
  • Castle Biosciences made up ﹤0.01% of Envestnet Asset Management's portfolio in Q2 2026, its #3449 holding.
  • Envestnet Asset Management first reported a position in Castle Biosciences in Q1 2021 and has held it in 22 quarters since.
  • Envestnet Asset Management's Castle Biosciences position peaked at $2.41M in Q4 2025.
  • 177 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2026.

Based on Envestnet Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.